FASLG and preeclampsia: The primary endpoint is a combination of aPL-related adverse pregnancy outcomes, including one or more gestational losses and preterm delivery before 34 weeks due to any of the following conditions: preeclampsia, eclampsia, or features arising from placental insufficiency. This study is expected to provide evidence on the effect of HCQ in pregnant women with persistently positive aPL antibodies and thus strengthen its evidence [52].